PEB - Pacific Edge Ltd

[TimmyTP]

Just watching the bid spread this morning--interesting to see the remainder of a late 100k order at 73 from last night (11k) grew to 21k while still showing only one bidder. I think (happy to be corrected) it's only instos that get to do that sort of thing. Am I right?

No, that's not correct. In fact, when increasing quantity, it is common is to create a new order for the difference, rather than amending the quantity. This is because qty amendments to existing orders would cause loss of priority in the depth.

[jonu]

No, that's not correct. In fact, when increasing quantity, it is common is to create a new order for the difference, rather than amending the quantity. This is because qty amendments to existing orders would cause loss of priority in the depth.

I get that Tim. I have to create a new order if the first one has already partly traded, which also attracts a new base brokerage fee. But in that situation I think it shows as a second bidder. In this case it still only shows one bid

[MAC]

“All data analysed, pre- and post-imputation showed that Cxbladder Detect had higher SNR and outperformed all other comparator tests, including FISH”

http://www.biomedcentral.com/content...015-0036-8.pdf

Why is the comparison to Uroysion(FISH) so important to Pacific Edge ?

Over the last few years Urovysion(FISH) has demonstrated that the adjunct market for bladder cancer diagnostic testing can be quite prospective.

The Urovysion price point is about the same as Cxbladder(detect) in the $550 to $600 range, and it is estimated that Urovysion(FISH) presently generates around US$120M in annual revenues.

The Pacific Edge goal is to be generating a humble NZ$100M in revenues in four year’s time from now.

Quite a humble and understated goal from Pacific Edge I’ve always held.

Especially when considering that Cxbladder(detect) not only is a superior test, it also has numerous more clinical applications than Urovysion(FISH) and all the others for that matter.

[psychic]

“All data analysed, pre- and post-imputation showed that Cxbladder Detect had higher SNR and outperformed all other comparator tests, including FISH”

http://www.biomedcentral.com/content...015-0036-8.pdf

Why is the comparison to Uroysion(FISH) so important to Pacific Edge ?

Over the last few years Urovysion(FISH) has demonstrated that the adjunct market for bladder cancer diagnostic testing can be quite prospective.

The Urovysion price point is about the same as Cxbladder(detect) in the $550 to $600 range, and it is estimated that Urovysion(FISH) presently generates around US$120M in annual revenues.

The Pacific Edge goal is to be generating a humble NZ$100M in revenues in four year’s time from now.

Quite a humble and understated goal from Pacific Edge I’ve always held.

Especially when considering that Cxbladder(detect) not only is a superior test, it also has numerous more clinical applications than Urovysion(FISH) and all the others for that matter.

Great find MAC and congratulations PEB/ Authors.
It's all a bit mind boggling really. NMP22, FISH etc have made big bucks over the years for the likes of Abbotts etc, approved and adopted as adjuncts to cytology/ cystoscopy but really, the tests fall well short on performance compared to CxBladder Detect.
So what is the potential revenue for a test that offers much more?
To say nothing of the potential earnings of CxBladder Triage which is scheduled for US launch in June. And that test is just out there on it's own - potentially saving the Health System the cost of full work ups for 80% of those presenting with Hematuria.
Then there is the tiny market outside of the US to consider, Colorectal, Melanoma and Gastric tests, etc etc,

$100m - a walk in the park.

[MAC]

Great find MAC and congratulations PEB/ Authors.
It's all a bit mind boggling really. NMP22, FISH etc have made big bucks over the years for the likes of Abbotts etc, approved and adopted as adjuncts to cytology/ cystoscopy but really, the tests fall well short on performance compared to CxBladder Detect.
So what is the potential revenue for a test that offers much more?
To say nothing of the potential earnings of CxBladder Triage which is scheduled for US launch in June. And that test is just out there on it's own - potentially saving the Health System the cost of full work ups for 80% of those presenting with Hematuria.
Then there is the tiny market outside of the US to consider, Colorectal, Melanoma and Gastric tests, etc etc,

$100m - a walk in the park.

Absolutely, and the healthcare market may well be more adoptive than it was when Pacific Edge set that goal over two years ago now also, it just seems that every year the system is looking for better and less invasive options, Obamacare coming along also boosting this type of tech and pushing for the enormous cost savings it brings to the sector;

Genomic Health with their breast cancer diagnostic test OncotypeDX recently announced a new goal of achieving US$1B in revenues by FY20.

Exact Sciences with their colon cancer diagnostic test Cologuard just announced that they have, within there first quarter following Medicare coverage, achieved 11,000 sales in that first three month period. Analyst consensus forecasts for Exact Sciences are US$45M revenues for this year, US$162M next year.

Pacific Edge are tracking around 6 to 12 months or so behind Exact Sciences in the commercialisation sequence, and although bladder cancer is the fourth most common cancer, it does show the potential in the market for them I reckon.

[skid]

Now all they have to do is sell it

Ive already covered the big name pharma companys partnered with Genomic

Here is what Exact Sciences are doing to ''partner up'' and market their product

http://www.beseengetscreened.com/get-connected/partners (this is on top of having the best product and FDA approved)

Its time for PEB to go out and partner up, or market their product in a similar manner-..Now they have some data,its time to act--not just sit and wait for the system to come to them.

[MAC]

You've not quite fully got it skid,

Genomic Health and Exact Sciences both market their products to general practitioners, to GP's, there are probably a million of them in the US, who really knows, and thus both companies require a distributing partner and a larger sales force just to work that sheer volume of contacts.

Cxbladder(detect) is marketed to specialist urologists, there are only 11,500 of them in the US, and an in-house sales force of only 20 is adequate for that market, particularly when they clump together in large urology groups of 100 or so. An entirely adequate plan by Pacific Edge for Cxbladder(detect) and the net margins will be much higher because of than.

For Cxbladder(triage) though I agree, I see that market as being very similar to Cologuard, and Pacific Edge may well respond with a distributing partner for that within the next year or so I suspect.

When the GP says you are now 40 and are due for a Colonoscopy, many like myself having experienced one, would say 'no thanks' I'll have a Cologuard test though, and it's a third of the cost for the insurer.

Cxbladder(triage) makes a similar prospect available for bladder cancer.

The GP may say, you are now 40 and, I see you have been a heavy smoker, or have been an ACTOS user, or have had blood in your urine in the past, you should have a Cystoscopy or a Cxbladder(triage) test, also for about one third the cost to the insurer.

[skid]

Everyone starts out at the GP --so your saying PEB is not marketing to the first link in the chain--whats to keep the doc from sending you for the only test he is aware of,even if its not as good.

Unless Im mistaken ,this is a screening test to rule out cancer--a first step to avoid costly follow ups?

so basically PEB has decided to market(if thats the right word) completely differently than these other companys that you have decided to compare to--(the succesful ones)

[Crystal Ball]

Everyone starts out at the GP --so your saying PEB is not marketing to the first link in the chain--whats to keep the doc from sending you for the only test he is aware of,even if its not as good.

Unless Im mistaken ,this is a screening test to rule out cancer--a first step to avoid costly follow ups?

so basically PEB has decided to market(if thats the right word) completely differently than these other companys that you have decided to compare to--(the succesful ones)

Must be about time for Snapiti to come in pour cold water on things, he s been quiet lately...

[MAC]

Yes, in fact they have gone one better, in offering what will be ultimately, by the end of next year, a total of four separate Cxbladder test products with four quite distinct markets.

Two products probably to be marketed to specialist urologists, and two products probably better marketed directly to GP's.

The advantage to Pacific Edge is that they can offer very high clinical test results with four separate products, rather than just a general single test which would cover all markets only adequately.

There's all the potential in the world,

Athough, we should not expect Pacific Edge to appoint a partner, if they are going too, until after the KP study is released and they announce the launch of Cxbladder(triage) in the US sometime soon.